WHO Pharmaceuticals Newsletter 2005, No. 01
(2005; 12 pages) View the PDF document
Table of Contents
Open this folder and view contentsREGULATORY MATTERS
Close this folderSAFETY OF MEDICINES
View the documentATAZANAVIRRITONAVIR - Not to be coadministered with omeprazole
View the documentCELECOXIB - Increased risk of cardiovascular events
View the documentDARBEPOETIN ALFA - Adverse outcomes associated with off-label dosing strategies
View the documentGALANTAMINE - Ineffective and possibly unsafe in mild cognitive impairment
View the documentGLUCOSAMINE - Concerns about hypercholesterolaemic effects
View the documentNAPROXEN - Long-term study indicates cardiovascular risk
View the documentNEVIRAPINE - Not recommended in women with CD4+ cell counts greater than 250 cells/mm3
View the documentPROPOFOL - Adverse events with both low- and high-rate infusions
View the documentROSUVASTATIN - More reports of rhabdomyolysis
Open this folder and view contentsDRUGS OF CURRENT INTEREST
Open this folder and view contentsFEATURE
 

NAPROXEN - Long-term study indicates cardiovascular risk

USA. The US FDA is alerting healthcare providers to emerging information from a long-term prevention trial, the Alzheimer's Disease Anti- Inflammatory Prevention Trial (ADAPT), that the risk of cardiovascular and cerebrovascular events may increase among patients taking naproxen, a non-steroidal antiinflammatory drug (NSAID).

The US FDA will be analysing all available information from these studies to determine whether additional regulatory action is needed. In the meantime, prescribers are cautioned:

• to carefully weigh the benefits and risks in patients currently on naproxen therapy,
• to always prescribe within the recommended dose of 250-500 mg twice a day and,
• to advise patients to adhere to the recommended daily dose indicated in over-thecounter naproxen preparations.


Several of the cyclooxygenase-2 (enzyme) specific inhibitor drugs (rofecoxib, celecoxib etc.) are currently under investigation for a full understanding of their adverse cardiovascular effects (see WHO Pharmaceuticals Newsletter No. 5, 2004 and section under 'Celecoxib' in this issue). Naproxen, a nonselective over-the-counter NSAID, is also being investigated to determine appropriate regulatory action. The US FDA is planning an advisory committee meeting in February 2005 to discuss the issues surrounding these drugs.

Reference:

FDA Alert for Health-care Providers (Naproxen), 23 December 2004. Available on the Internet at www.fda.gov

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: October 29, 2018